Source:http://linkedlifedata.com/resource/pubmed/id/15980161
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2005-8-17
|
| pubmed:abstractText |
Less than 50% of all high-grade non-Hodgkin lymphoma (NHL) patients experience lasting disease-free survival. Risk-adapted treatment strategies require better tools for prediction of outcome. This investigation aimed to assess the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two to three cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1514-23
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15980161-Adult,
pubmed-meshheading:15980161-Aged,
pubmed-meshheading:15980161-Aged, 80 and over,
pubmed-meshheading:15980161-Antineoplastic Agents,
pubmed-meshheading:15980161-Female,
pubmed-meshheading:15980161-Fluorodeoxyglucose F18,
pubmed-meshheading:15980161-Humans,
pubmed-meshheading:15980161-Lymphoma, Non-Hodgkin,
pubmed-meshheading:15980161-Male,
pubmed-meshheading:15980161-Middle Aged,
pubmed-meshheading:15980161-Positron-Emission Tomography,
pubmed-meshheading:15980161-Survival Analysis
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.
|
| pubmed:affiliation |
Department of Clinical Oncology, Guy's and St. Thomas' Hospital, London, UK. george.mikhaeel@gstt.nhs.uk
|
| pubmed:publicationType |
Journal Article
|